Contributions
Abstract: EP1597
Type: Poster Sessions
Abstract Category: Therapy - Immunomodulation/Immunosuppression
Introduction: The Effect of teriflunomide in a progressive multiple sclerosis (MS) population is not well characterized
Objective: We wished to explore the side effect profile and efficacy of teriflunomide in a group of patients with primary (PPMS) and secondary progressive (SPMS) multiple sclerosis.
Aims: To describe side effects and efficacy in a PPMS and SPMS as measured by timed 25 foot walk (T25FW) and expanded disability status scale (EDSS).
Methods: We conducted a single-center retrospective observational analysis of medical records and available comprehensive longitudinal investigation in MS database (CLIMB) information for patients labelled by clinicians as having PPMS or SPMS at a tertiary academic center with teriflunomide from 2012-2017. Patients also were required to be ≥ 40 years old and an EDSS ≥ 3.5 at the initiation of treatment with teriflunomide. EDSS and 25-foot walk time in the year before treatment and after treatment were analyzed. Analysis of T25FW prior to start and one year after start was compared with Wilcoxon rank sum testing.
Results: Twenty-nine patients were included in the study. Mean EDSS did not differ prior to teriflunomide start and after one year (n=29, 6.29 vs 6.33, p=0.98.) Mean T25W also did not differ prior to teriflunomide start and at one year (n=19, 10.5s vs. 10.8, p=0.85.) Teriflunomide was generally well tolerated without serious tolerability or safety concerns in this small population.
Conclusions: Patients did not worsen over the course of one year as measured by EDSS and T25FW while on teriflunomide. Further characterization of this population and comparison to other cohorts is needed.
Disclosure: Natalie Erlich: none
Tanuja Chitnis: Dr. Chitnis has received consulting/advisory fees from Biogen and Celgene. She serves on clinical trial advisory committees for Novartis and Sanofi-Genzyme.
James Stankiewicz: Dr. Stankiewicz has received consulting/advisory fees from
Biogen Idec, Genzyme, Celgene, Bayer, EMD Serono, Genentech, and Novartis.
Abstract: EP1597
Type: Poster Sessions
Abstract Category: Therapy - Immunomodulation/Immunosuppression
Introduction: The Effect of teriflunomide in a progressive multiple sclerosis (MS) population is not well characterized
Objective: We wished to explore the side effect profile and efficacy of teriflunomide in a group of patients with primary (PPMS) and secondary progressive (SPMS) multiple sclerosis.
Aims: To describe side effects and efficacy in a PPMS and SPMS as measured by timed 25 foot walk (T25FW) and expanded disability status scale (EDSS).
Methods: We conducted a single-center retrospective observational analysis of medical records and available comprehensive longitudinal investigation in MS database (CLIMB) information for patients labelled by clinicians as having PPMS or SPMS at a tertiary academic center with teriflunomide from 2012-2017. Patients also were required to be ≥ 40 years old and an EDSS ≥ 3.5 at the initiation of treatment with teriflunomide. EDSS and 25-foot walk time in the year before treatment and after treatment were analyzed. Analysis of T25FW prior to start and one year after start was compared with Wilcoxon rank sum testing.
Results: Twenty-nine patients were included in the study. Mean EDSS did not differ prior to teriflunomide start and after one year (n=29, 6.29 vs 6.33, p=0.98.) Mean T25W also did not differ prior to teriflunomide start and at one year (n=19, 10.5s vs. 10.8, p=0.85.) Teriflunomide was generally well tolerated without serious tolerability or safety concerns in this small population.
Conclusions: Patients did not worsen over the course of one year as measured by EDSS and T25FW while on teriflunomide. Further characterization of this population and comparison to other cohorts is needed.
Disclosure: Natalie Erlich: none
Tanuja Chitnis: Dr. Chitnis has received consulting/advisory fees from Biogen and Celgene. She serves on clinical trial advisory committees for Novartis and Sanofi-Genzyme.
James Stankiewicz: Dr. Stankiewicz has received consulting/advisory fees from
Biogen Idec, Genzyme, Celgene, Bayer, EMD Serono, Genentech, and Novartis.